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ABSTRACT 
This work reports the synthesis and characterization of new benzimidazole-cyclohexanone 
derivatives 3a-d, 4a-d and 5a-d under different reaction conditions. The intermediates and 
final compounds were purified and their chemical structures were elucidated using 1H-NMR, 
13C-NMR and mass spectral data. 
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1. INTRODUCTION 
Benzimidazole derivatives are of wide interest because of their diverse biological activity and 
clinical applications, the benzimidazole ring is present in some clinically used 
drugs, such as proton pump inhibitors, the antiviral enviroxime and the antihistaminic 
astemizole, but it may also display antimycobacterial, antimicrobial, anticonvulsant, 
analgesic, anti-inflammatory, anti-diabetic, antiprotozoal, antipsychotic, antioxidant and 
antitumoral properties[1]. 
Some of them like thiabendazole, mebendazole or albendazole are widely used 
asantihelmintic drugs [2], due to their ability to bind selectively with high affinity to the β-
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subunit of helminthmicrotubule protein [3]. Benzimidazolone derivatives also cover a broad 
range of biological activities, including opioid receptor antagonistic [4] or antinociceptive [5] 
effects, and potassium channel activation [6]. 
The benzimidazolone and benzimidazolothione ring structures possess a number of 
interesting biologically properties and constitute a constrained ring system with two nitrogen 
atoms linked by an ethylene bridge, as diazoles ring system [7,8]. 
Cyclohexanone-analogous, which designed based on the curcumin corestructure, have been 
discovered as potential EGFR inhibitors [9], drugs for the treatment of ER-negative breast 
cancer [10]. 
 
2. RESULTS AND DISCUSSION 
From this point of view, in the present study, new Benzimidazole-cyclohexanone derivatives 
were synthesized. We used two-step procedure with different reagents for synthesis of twelve 
benzimidazole derivatives. 
In the first step, A similar procedure involving the addition of o-PDAs to 2- 
acetylbutyrolactone and analogues, was recently used by our group to access benzimidazole-
butyrolactone derivatives [11]. 
By examining a variety of reaction conditions, we have found that the process is usually most 
efficient using an equimolar mixture of 2- acetylcyclohexanone 1 and o-PDAs in ethanol at 
room temperature. Under these conditions all the intermediates were obtained in good 
yields(60–80%) and readily isolated by simple recrystallization (Scheme 1). The structures of 
all these synthons 2a–d have been established on the basis of 1H and 13C NMR. 




















Form B Form Ao-PDAs
a. R1 = R2 = H
c. R1 = Cl, R2 = H
b. R1 = CH3, R
2 = H










Table 1. Conditions of formation and physical data of 2a-d in ethanol at 25 °C 
 
Compounds R1 R2 Time(h) Yield (%) mp (°C) Nature and color 
2a H H 24 60 191-193 Brown powder 
2b CH3 H 24 65 195-197 Yellow powder 
2c Cl H 24 73 204-206 White powder 
2d H NO2 24 80 207-209 Yellow powder 
 
The next step consisted in the preparation of the benzimidazole ring by treating the isolated 
(Z)-2-(1-aminoethylidene)cyclohexanones 2a–d either with N,N-dimethylformamide, 
dimethylacetal (DMF–DMA) in refluxing CH2Cl2 in the presence of catalytic amounts of 
NEt3 lasting from 10 to 15 h, triphosgene in CH2Cl2 and allowed to stir for 3 h starting from 
0°C up to room temperature, carbon disulfide in DMSO at room temperature of NEt3, 
respectively, benzimidazole 3a–d, benzimidazolone 4a–d, or benzimidazole-2-thione 5a–d 
attached to a cyclohexanone moiety via a 1-aminoethylidene moiety(Scheme 2)[11]. 
 
 
All compounds 3-5 were characterized by the various spectroscopic methods. 
Their physical properties are summarized in table 2. 





Table 2. Conditions of formation and physical data of 3-5 
 




3a H H reflux CH2Cl2 10 85 173-175 
Yellow 
powder 
3b CH3 H reflux CH2Cl2 12 90 202-204 
Yellow 
powder 
3c Cl H reflux CH2Cl2 15 75 207-209 
Off white 
powder 
3d H NO2 reflux CH2Cl2 12 65 213-215 
Yellow 
powder 
4a H H 0°C CH2Cl2 3h 90 223-225 
Grey 
powder 
4b CH3 H 0°C CH2Cl2 3h 70 229-230 
Brown 
powder 
4c Cl H 0°C CH2Cl2 3h 88 235-236 
Yellow 
powder 
4d H NO2 0°C CH2Cl2 3h 90 242-243 
White 
powder 
5a H H rt DMSO 48h 95 225-226 Orange powder 
5b CH3 H rt DMSO 48h 85 234-235 
Yellow 
powder 
5c Cl H rt DMSO 48h 50 231-232 Brown powder 






All chemicals were obtained from Aldrich. Melting points were taken on a Thomas 
Hoover apparatus and are uncorrected. Nuclear magnetic resonance spectra were 
obtained with a Bruker AC 300 at 300 MHz (1H) or 75 MHz (13C). The chemical shifts are 
reported in ppm(δ-scale) relative to internal TMS and coupling constants are reported in 
Hertz (Hz). High-resolution mass spectrometry HRMS spectra were obtained with a GC 
TOF Waters and Waters Q / TOF Ultima. 
General procedure for synthesis of 2a-d 
In 20 mL ethanol, a  2-acetylcyclohexanone (1 mL, 0.01 mol) was reacted with o-
phenylenediamines (1.08 g, 0.01 mol).The mixture was stirred at room temperature 24 
hours under magneticstirring, the compounds precipitate in the reaction media. After 
filtration under reduced pressure, the corresponding compounds 2a-d were purified by 
recrystallization from ethanol.  
General procedure for synthesis of  3a-d 




An equimolar amount of (Z)-2-(2 Aminophenylamino) ethylidene) cyclohexanones 2a-d 
(1.8 mmol) and DMF DMA (1.8 mmol) was allowed to stir under refluxing 
dichloromethane (20 mL) for 10 to 15 h (the reactions are monitored by TLC) in the 
presence of few drops of triethylamine. The precipitating products were removed by 
evaporation and treatment with diethyl ether. The pure compounds 3a-d were recrystallized 
from ethanol.  
General procedure for synthesis of 4a-d 
A mixture of (Z)-2-(2 Aminophenylamino) ethylidene) cyclohexanones 2a-d (0.02 mol) and 
trimethylamine (0.04 mol) in dichloromethane (40 mL) was placed in an ice/water bath 
under constant magnetic stirring. Triphosgene (6.6 mmol) was gradually added over a period 
of 3 h. The reaction was quenched in ice/water and the product was extracted using 
dichloromethane (3 x 40 mL). The organic fraction was dried over anhydrous sodium 
sulfate. Solid products of 4a-d were obtained upon evaporation of the dichloromethane 
solution.  
General procedure for synthesis of  5a-d 
A mixture of (Z)-2-(2 Aminophenylamino) ethylidene) cyclohexanones 2a-d (2 mmol) and 
thiosulfide (2 mmol) in DMSO (30 mL) was stirred at room temperature for 48 h in the 
presence of a few drops of NEt3. The reaction mixture was then slowly versed in ice/water 
under stirring. Compounds 5a-d were precipitated, collected by filtration and washed with 
water.  
(Z)-2-[1-(2-Aminophenylamino)ethylidene)]cyclohexanone 2a  
1H NMR (300 MHz, DMSO-d6): δ 1.60-1.70 (m, 4H, CH2), 1.76 (s, 3H, CH3), 2.26 and 2.36 
(2t, J 3.7 Hz, 4H, CH2), 3.75 (s, 2H, NH2), 6.80-7.30 (m, 4H, Harom), 9.26 (s, 1H, NH); 
13C 
NMR (75 MHz, DMSO-d6): δ 17.5 (CH3), 22.8, 26.5, 27.4 and 41.0 (4 x CH2), 99.5 (CO-
C=C), 119.3, 124.5, 126.5, 127.6, 128.4 and 142.8 (Carom), 155.1 [=C(CH3)-NH], 202.4 
(C=O); HRMS (ESI+): m/z calcd for [C14H18N2O+Na]
+: 253.1330; found: 253.1215. 
(Z)-2-[1-(2-Amino-4-methylphenylamino)ethylidene]cyclohexanone 2b 
1H NMR (300 MHz, DMSO-d6): δ 1.64-1.76 (m, 4H, CH2), 1.15 and 1.72 (2s, 6H, CH3), 2.20 
and 2.26 (2t, J 3.7 Hz, 4H, CH2), 2.95 (s, 2H, NH2), 7.10-7.80 (m, 3H, Harom), 8.80 (s, 1H, 
NH); 13C NMR (75 MHz, DMSO-d6): δ 17.6 and 24.2 (2 x CH3), 22.5, 26.4, 27.4 and 40.0 (4 
x CH2), 100.1 (CO-C=C), 116.5, 119.2, 122.4, 128.7, 139.1 and 143.4 (Carom), 156.3 
[=C(CH3)-NH], 200.8 (C=O); HRMS (ESI
+): m/z calcd for [C15H20N2O+Na]
+: 267.1550; found: 
267.1346. 





1H NMR (300 MHz, DMSO-d6): δ 1.60-1.70 (m, 4H, CH2), δ 1.80 (s, 3H, CH3), 2.25 and 2.37 
(2t, J 4.1 Hz, 4H, CH2), 3.98 (s, 2H, NH2), 6.60-7.10 (m, 3H, Harom), 9.16 (s, 1H, NH); 
13C 
NMR (75 MHz, DMSO-d6): δ 17.3 (CH3), 22.5, 26.6, 27.5 and 41.2 (4 x CH2), 201.4 (CO-
C=C), 115.6, 118.5, 123.4, 129.8, 134.1 and 145.7 (Carom), 157.3 [=C(CH3)- NH], 201.8 
(C=O); HRMS (ESI+): m/z calcd for [C14H17ClN2O+Na]
+: 287.0908; found: 287.0917. 
(Z)-2-[1-(2-Amino-5-nitrophenylamino)ethylidene]cyclohexanone 2d 
1H NMR (300 MHz, DMSO-d6): δ 1.64-1.75 (m, 4H, CH2), 2.10 (s, 3H, CH3), 2.24 and 2.37 
(2t, J 3.6 Hz, 4H, CH2), 4.00 (s, 2H, NH2), 6.80-7.70 (m, 3H, Harom), 9.40 (s, 1H, NH); 
13C 
NMR (75 MHz, DMSO-d6): δ 17.8 (CH3), 23.0, 26.2, 27.6 and 39.8 (4 x CH2), 99.0 (CO-
C=C), 114.2, 126.1, 125.5, 125.6, 136.1 and 152.6 (Carom), 156.4 [=C(CH3)-NH], 200.5 
(C=O); HRMS (ESI+): m/z calcd for [C14H17N3O3+Na]
+: 298.1210; found: 298.1140. 
(Z)-2-[1-(1H-Benzo[d]imidazol-1-yl)ethylidene]cyclohexanone 3a 
1H NMR (300 MHz, DMSO-d6): δ 1.69-1.74 (m, 4H, CH2), 1.85 (s, 3H, CH3), 2.39 and 2.40 
(2t, J 3.9 Hz, 4H, CH2), 6.60-7.30 (m, 4H, Harom), 9.30 (s, 1H, N=CH-N); 
13C NMR (75 
MHz, DMSO-d6): δ 17.5 (CH3), 22.7, 26.4, 27.3 and 41.2 (4 x CH2), 100.6 (CO-C=C), 
115.5, 119.1, 124.4, 126.6, 128.2 and 142.8 (Carom), 153.5 (N=CH-N), 157.0 [=C(CH3)-
N<], 198.9 (C=O); HRMS (ESI+): m/z calcd for [C15H16N2O+Na]
+: 263.1214; found: 
263.1109. 
(Z)-2-[1-(5-Methyl-1H-benzo[d]imidazol-1-yl)ethylidene]cyclohexanone 3b  
1H NMR (300 MHz, DMSO-d6): δ 1.20 and 1.83 (2s, 6H, CH3), 1.68-1.75 (m, 4H, CH2), 2.41 
and 2.43 (2t, J 3.8 Hz, 4H, CH2), 6.55-7.20 (m, 3H, Harom), 9.32 (s, 1H, N=CH-N); 
13C 
NMR (75 MHz, DMSO-d6): δ 17.2 and 23.6 (2 x CH3), 22.5, 26.3, 27.1 and 40.6 (4 x CH2), 
99.7 (CO-C=C), 115.8, 119.2, 124.5, 126.5, 129.0 and 143.0 (Carom), 153.4 (N=CH-N), 
156.5 [=C(CH3)-N<], 199.8 (C=O); HRMS (ESI
+): m/z calcd for [C16H18N2O +Na]
+: 
277.1302; found: 277.1256. 
(Z)-2-[1-(5-Chloro-1H-benzo[d]imidazol-1-yl)ethylidene]cyclohexanone  3c  
1H NMR (300 MHz, DMSO-d6): δ 1.66-1.73 (m, 4H, CH2), 1.80 (s, 3H, CH3), 2.40 and 2.42 
(2t, J 3.9 Hz, 4H, CH2), 6.52-6.98 (m, 3H, Harom), 9.25 (s, 1H, N=CH-N); 
13C NMR (75 
MHz, DMSO-d6): δ 17.6 (CH3), 22.6, 26.5, 27.2 and 41.4 (4 x CH2), 99.6 (CO-C=C), 116.6, 
119.6, 123.1, 129.8, 134.7 and 145.2 (Carom), 153.3 (N=CH-N), 156.9 [=C(CH3)-N<], 199.7 
(C=O); HRMS (ESI+): m/z calcd for [C15H15ClN2O+Na]
+: 297.0856; found: 297.0804. 





1H NMR (300 MHz, DMSO-d6): δ 1.70-1.76 (m, 4H, CH2), 2.10 (s, 3H, CH3), 2.42 and 2.43 
(2t, J 3.8 Hz, 4H, CH2) , 6.52-7.03 (m, 3H, Harom), 9.20 (s, 1H, N=CH-N); 
13C NMR (75 
MHz, DMSO-d6): δ 15.2 (CH3), 22.9, 26.7, 27.5 and 40.5 (4 x CH2), 99.8 (CO-C=C), 113.7, 
123.5, 125.1, 125.7, 135.3 and 152.5 (Carom), 153.3 (N=CHN). 156.2 [=C(CH3)-N], 200.4 
(C=O); HRMS (ESI+): m/z calcd for [C15H15N3O3+Na]
+: 308.1055; found: 308.0908. 
(Z)-1-[1-(2-oxocyclohexylidene)ethyl]-1H-benzo[d]imidazol-2(3H)-one 4a 
1H NMR (300 MHz, DMSO-d6): δ 1.66-1.75 (m, 4H, CH2), 2.45 (s, 3H, CH3), 2.28 and 2.44 
(2t, J 3.8 Hz, 4H, CH2), 7.10-7.62 (m, 4H, Harom), 9.32 (s, 1H, NH); 
13C NMR (75 MHz, 
DMSO-d6): δ 19.2 (CH3), 22.5, 26.3, 27.4 and 40.7 (4 x CH2), 102.8 (CO-C=C), 108.7, 109.5, 
121.0, 121.3, 128.4 and 129.2 (Carom), 138.1 [=C(CH3)- N], 149.8 and 198.9 (2 x C=O); 
HRMS (ESI+): m/z calcd for [C15H16N2O2+Na]
+: 279.1127; found: 279.1093. 
(Z)-5-Methyl-1-[1-(2-oxocyclohexylidene)ethyl]-1H-benzo[d]imidazol-2(3H)-one 4b 
1H NMR (300 MHz, DMSO-d6): δ 1.19 and 2.35 (2s, 6H, CH3), 1.62-1.73 (m, 4H, CH2), 2.30 
and 2.46 (2t, J 3.9 Hz, 4H, CH2), 6.80-7.77 (m, 3H, Harom), 9.29 (s, 1H, NH); 
13C NMR (75 
MHz, DMSO-d6): δ 18.7 and 19.2 (2 x CH3), 22.5, 26.2, 27.4 and 40.9 (4 x CH2), 100.8 (CO-
C=C), 109.0, 109.3, 120.5, 121.4, 128.8 and 129.7 (Carom), 138.9 [=C(CH3)-N], 148.2 and 
203.3 (2 x C=O); HRMS (ESI+): m/z calcd for [C16H18N2O2+Na]
+: 293.1304; found: 
293.1264. 
(Z)-5-Chloro-1-[1-(2-oxocyclohexylidene)ethyl]-1H-benzo[d]imidazol-2(3H)-one 4c  
1H NMR (300 MHz, DMSO-d6): δ 1.64-1.73 (m, 4H, CH2), 2.15 (s, 3H, CH3), 2.28 and 2.41 
(2t, J 3.9 Hz, 4H, CH2), 7.20-7.82 (m, 3H, Harom), 9.20 (s, 1H, NH); 
13C NMR (75 MHz, 
DMSO-d6): δ 19.6 (CH3), 22.5, 26.2, 27.5 and 41.0 (4 x CH2), 99.6 (CO-C=C), 108.2, 110.2, 
120.2, 122.0, 128.3 and 129.8 (Carom), 142.3 [=C(CH3)- N], 151.8 and 198.8 (2 x C=O); 
HRMS (ESI+): m/z calcd for [C15H15ClN2O2+Na]
+: 313.0708; found: 313.0680. 
(Z)-6-Nitro-1-[1-(2-oxocyclohexylidene)ethyl]-1H-benzo[d]imidazol-2(3H)-one 4d  
1H NMR (300 MHz, DMSO-d6): δ 1.63-1.75 (m, 4H, CH2), 2.18 (s, 3H, CH3), 2.25 and 2.46 
(2t, J 3.9 Hz, 4H, CH2), 7.50-8.61 (m, 3H, Harom), 9.32 (s, 1H, NH); 
13C NMR (75 MHz, 
DMSO-d6): δ 19.9 (CH3), 22.6, 26.5, 27.1 and 40.6 (4 x CH2), 99.8 (CO-C=C), 108.6, 109.5, 
120.6, 121.5, 128.1 and 128.8 (Carom), 142.4 [=C(CH3)-N], 152.0 and 198.9 (2 x C=O); 
HRMS (ESI+): m/z calcd for [C15H15N3O4+Na]
+: 324.1040; found: 324.0923. 
(Z)-2-[1-(2-Thioxo-2,3-dihydrobenzo[d]imidazol-1- yl) ethylidene]cyclohexanone 5a 




1H NMR (300 MHz, DMSO-d6): δ 1.62-1.74 (m, 4H, CH2), 2.23 (s, 3H, CH3), 2.24 and 2.47 
(2t, J 3.7 Hz, 4H, CH2), 6.68- 6.98 (m, 4H, Harom), 12.76 (s, 1H, NH); 
13C NMR (75 MHz, 
DMSO-d6): δ 17.5 (CH3), 22.6, 26.5, 27.5 and 40.8 (4 x CH2), 100.4 (CO-C=C), 110.7, 111.5, 
123.7, 127.4, 131.6 and 132.5 (Carom), 141.3 [=C(CH3)- N], 165.2 (C=S), 199.6 (C=O); 
HRMS (ESI+): m/z calcd for [C15H16N2OS+Na]
+: 295.0920; found: 265.0502. 
(Z)-2-[1-(5-Methyl-2-thioxo-2,3-dihydrobenzo[d]imidazol-1yl)ethylidene]cyclohexanone 
5b  
1H NMR (300 MHz, DMSO-d6): δ 1.64-1.77 (m, 4H, CH2), 2.42 and 2.50 (2s, 6H, CH3), 2.25 
and 2.36 (2t, J 3.8 Hz, 4H, CH2), 6.60-7.52 (m, 3H, Harom), 11.76 (s, 1H, NH); 
13C NMR (75 
MHz, DMSO-d6): δ 16.9 and 17.2 (2 x CH3), 22.6, 26.5, 27.5 and 41.0 (4 x CH2), 99.8 (CO-
C=C), 104.4, 110.1, 122.6, 124.5, 138.2 and 143.1 (Carom), 141.0 [=C(CH3)-N],165.8 (C=S), 
200.1 (C=O); HRMS (ESI+): m/z calcd for [C16H18N2OS+Na]
+: 303.1029; found: 303.0908. 
(Z)-2-[1-(5-Chloro-2-thioxo-2,3-dihydrobenzo[d]imidazol-1-yl)ethylidene]cyclohexanone 
5c 
1H NMR (300 MHz, DMSO-d6): δ 1.62-1.74 (m, 4H, CH2), 2.23 (s, 3H, CH3), 2.31 and 2.39 
(2t, J 3.7 Hz, 4H,CH2), 6.52-7.26 (m, 3H, Harom), 12.29 (s, 1H, NH); 
13C NMR (75 MHz, 
DMSO-d6): δ 17.7 (CH3), 22.5, 26.3, 27.5 and 41.1 (4 x CH2), 99.1 (CO-C=C), 101.8, 107.5, 
119.2, 121.2, 125.3 and 131.6 (Carom), 142.0 [=C(CH3)-N], 166.2 (C=S); 200.6 (C=O); 
HRMS (ESI+): m/z calcd for [C15H15ClN2OS+Na]
+: 329.0540; found: 329.0204. 
(Z)-2-[1-(6-Nitro-2-thioxo-2,3-dihydrobenzo[d]imidazol-1-yl)ethylidene]cyclohexanone 
5d  
1H NMR (300 MHz, DMSO-d6): δ 1.65-1.76 (m, 4H, CH2), 2.25 (s, 3H, CH3), 2.35 and 2.47 
(2t, J 3.7 Hz, 4H, CH2), 6.90-7.14 (m, 3H, Harom), 11.35 (s, 1H, NH); 
13C NMR (75 MHz, 
DMSO-d6): δ 17.6 (CH3), 22.7, 25.8, 26.9 and 39.8 (4 x CH2), 99.6 (CO-C=C), 105.3, 107.5, 
120.3, 127.2, 131.9 and 140.6 (Carom), 142.1 [=C(CH3)- N], 166.8 (C=S), 201.7 (C=O); 
HRMS (ESI+): m/z calcd for [C15H15N3O3S+Na]
+: 340.0712; found: 340.0744. 
 
4. CONCLUSION 
A new series of benzimidazole-cyclohexanone 3a-b, 4a-b and 5a-b were synthesized by the 
reaction of (Z)-2-(1-aminoethylidene)cyclohexanones with different electrophilic reagents as 
DMF-DMA, triphosgene and carbon disulfide. All these compounds were obtained in 
moderate-to good yields under mild operating conditions. The determination of the structural 
features of these intermediates was first performed by solution 1H, 13C NMR and HRMS. 
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